Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of BMS-919373 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2011
At a glance
- Drugs BMS 919373 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 06 Dec 2011 Status changed from not yet recruiting to suspended as reported by Australian New Zealand Clinical Trials Registry.
- 08 Jun 2011 New trial record